Aurinia Pharmaceuticals Stock Investor Sentiment
| AUPH Stock | USD 9.12 0.14 1.56% |
Under 69 percent of all Aurinia Pharmaceuticals' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that a large number of traders are confidant. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
Aurinia Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Aurinia Pharmaceuticals that are available to investors today. That information is available publicly through Aurinia media outlets and privately through word of mouth or via Aurinia internal channels. However, regardless of the origin, that massive amount of Aurinia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aurinia Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aurinia Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aurinia Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aurinia Pharmaceuticals alpha.
Aurinia Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 4650 shares by Billen Daniel of Aurinia Pharmaceuticals at 11.26 subject to Rule 16b-3 | 10/21/2024 |
2 | Disposition of 8733 shares by Jayne David R.w. of Aurinia Pharmaceuticals subject to Rule 16b-3 | 10/25/2024 |
3 | Earnings call Aurinia Pharmaceuticals announced a 24 percent increase in total net revenue | 11/07/2024 |
4 | Disposition of 5241 shares by Smith Karen L. of Aurinia Pharmaceuticals at 8.43 subject to Rule 16b-3 | 11/11/2024 |
5 | Aurinia Pharmaceuticals director Karen Smith sells 44,181 in stock | 11/13/2024 |
6 | Aurinia to Participate in Jefferies London Healthcare Conference | 11/14/2024 |
7 | Acquisition by Jayne David R.w. of 18641 shares of Aurinia Pharmaceuticals at 8.24 subject to Rule 16b-3 | 11/21/2024 |
8 | Disposition of 25146 shares by Knappertz Volker of Aurinia Pharmaceuticals at 5.48 subject to Rule 16b-3 | 11/29/2024 |
9 | Acquisition by Tang Kevin of 300000 shares of Aurinia Pharmaceuticals at 8.91 subject to Rule 16b-3 | 12/05/2024 |
10 | Acquisition by Tang Kevin of 500000 shares of Aurinia Pharmaceuticals at 9.09 subject to Rule 16b-3 | 12/09/2024 |
11 | Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options | 12/10/2024 |
12 | Sunbelt Securities Inc. Cuts Stock Holdings in Aurinia Pharmaceuticals Inc. | 12/12/2024 |
13 | Aurinia Pharmaceuticals laying off dozens in Montgomery County | 12/24/2024 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |